Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

por Zabriskie, M S, Eide, C A, Yan, D, Vellore, N A, Pomicter, A D, Savage, S L, Druker, B J, Deininger, M W, O'Hare, T
Publicado 2016

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymp...

por Tharkar-Promod, S, Johnson, D P, Bennett, S E, Dennis, E M, Banowsky, B G, Jones, S S, Shearstone, J R, Quayle, S N, Min, C, Jarpe, M, Mosbruger, T, Pomicter, A D, Miles, R R, Chen, W Y, Bhalla, K N, Zweidler-McKay, P A, Shrieve, D C, Deininger, M W, Chandrasekharan, M B, Bhaskara, S
Publicado 2018